Maximiliano van Kooten

Suggest Changes
Learn More
5111 Background: GEM is active in recurrent epithelial ovarian cancer. OX activity in ovarian cancer is similar to cisplatin in first-line therapy and PAC in nonrefractory relapses. This multicenter,(More)
The aim of this study was to examine the efficacy and safety of both oxaliplatin as a single agent and oxaliplatin in combination with dailyx5 bolus 5-fluorouracil and folinic acid (5-FU/FA, Mayo(More)
  • 1